Weaker prospects for pharmaceutical giant Novo Nordisk A/S NVS have prompted Denmark’s economic ministry to cut its 2025 GDP forecast, now expecting just 1.4% growth, down 1.5 percentage points from May’s projection.
Growth is seen rebounding to 2.1% in 2026, up 0.7 points. Employment is still rising and inflation is projected to stay below 2%. The ministry said U.S. tariff hikes will further weigh on exports and global activity, while an EU-U.S. trade framework reduces uncertainty around sales terms.
Also Read: New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data
Denmark’s growth outlook is being shaped by consumer strength, exports, and Novo Nordisk’s trajectory. Rising household demand, boosted by wage gains, tax cuts, and high employment, is supporting private consumption.
Reuters noted Denmark’s strong 2024 growth was among Europe’s highest, with Novo Nordisk alone contributing one-fifth of employment gains. But headwinds are mounting.
U.S. tariffs, for example, dragged exports sharply lower in early 2025, cutting forecast growth to 0.9% from 4.3% in May.
Meanwhile, Novo Nordisk—maker of Wegovy and Ozempic—announced a global hiring freeze and lowered its 2025 sales forecast to 8–14% growth, down from 13–21%, citing slower uptake of branded GLP-1 drugs and rising competition from Eli Lilly and compounded alternatives.
Still, Denmark’s economy ministry raised its 2026 GDP outlook to 2.1%, pointing to stronger private and public spending.
Price Action: NVO stock is up 0.04% at $56.14 at the last check on Friday.
Read Next:
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Great Job Vandana Singh & the Team @ Benzinga – Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals Source link for sharing this story.
